Tysabri and PML: Key Symptoms and Monitoring Timeline

From General Health Information to Specific Legal Context

If you or a loved one has taken Tysabri and are now experiencing new neurological symptoms like vision changes, weakness, or confusion, understanding the timing and documentation of these signs is critical. Decades of pharmacovigilance research have established a clear link between Tysabri use and progressive multifocal leukoencephalopathy (PML), a serious brain infection. This page outlines the key symptoms, typical onset windows, and what medical records should capture for informed decision-making.

Bridging Clinical Risk and Legal Recourse

For individuals who have been prescribed Tysabri—a medication used for certain autoimmune conditions—the potential development of PML represents a serious adverse event that transcends routine clinical management. This shift in perspective moves from population-level health education to individual exposure scenarios, where questions of liability, timing, and legal recourse become paramount. The occupational exposure concern here is not about workplace hazards in the traditional sense, but rather about the patient’s exposure to a pharmaceutical agent within a therapeutic context, and the subsequent need to understand legal frameworks—such as Virginia’s statute of limitations—that govern claims related to such exposure. This transition thus bridges general health literacy with specific legal and occupational risk assessment.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. PML typically occurs only in immunocompromised patients, and Tysabri's mechanism of action—blocking lymphocyte migration into the central nervous system—creates a state of localized immunosuppression that allows JC virus reactivation. The label identifies three key risk factors for PML development: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

Clinical presentation of PML can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, PML can still occur, and outcomes are often poor, with many patients experiencing severe disability or death. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This reduces normal immune surveillance in the brain, allowing JC virus to replicate unchecked in oligodendrocytes, leading to demyelination and neuronal damage. The label notes that PML "typically only occurs in patients who are immunocompromised" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and Tysabri-induced immunosuppression is sufficient to create this vulnerability.

Virginia Statute of Limitations for Tysabri-Related PML Claims

For patients in Virginia who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability claim. In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can vary. Symptoms may appear months to years after starting Tysabri, and diagnosis can be delayed due to the nonspecific nature of early symptoms. The label states that PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), but cases have been reported after shorter exposure. Adequacy of warnings is a central issue in potential litigation. The boxed warning and risk mitigation program (TOUCH Prescribing Program) are designed to inform patients and providers of PML risk. The label requires that patients "be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficient to convey the severity and likelihood of PML, especially for patients with multiple risk factors. The label also notes that Tysabri "should not be used in combination with immunosuppressants or inhibitors of TNF-α" in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), but prior immunosuppressant use is a risk factor for PML.

Attorney Considerations for Affected Patients

Attorney-related considerations for affected patients include the need to document the timeline of Tysabri exposure, onset of symptoms, and diagnosis. Medical records should be reviewed to determine whether risk factors were assessed and whether monitoring protocols were followed. The statute of limitations in Virginia may begin at the time of diagnosis or when the patient became aware of the link between Tysabri and PML. Given the severity of PML, prompt legal consultation is advisable to preserve claims. In summary, Tysabri carries a known risk of PML, with specific risk factors identified in the prescribing information. Patients in Virginia who develop PML should be aware of the statute of limitations and the importance of timely legal action. The adequacy of warnings and the timeline between exposure and harm are critical factors in any potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Request a Free Case Review